Stockscreener 앱 받기
1.21
5.47%
-0.07
전일 마감가:
$1.28
열려 있는:
$1.21
하루 거래량:
595
Relative Volume:
10.91
시가총액:
$N/A
수익:
$3.13M
순이익/손실:
$-40.29M
주가수익비율:
-0.3781
EPS:
-3.2
순현금흐름:
$-33.08M
1주 성능:
-5.47%
1개월 성능:
-60.53%
6개월 성능:
+427.32%
1년 성능:
+221.67%
1일 변동 폭
$1.21
$1.21
1주일 범위
$1.21
$1.21
52주 변동 폭
$1.21
$1.28
Trevena Inc Stock (TRVN) Company Profile
TRVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVN
Trevena Inc
|
1.21 | 0 | 3.13M | -40.29M | -33.08M | -3.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevena Inc Stock (TRVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-15 | 개시 | Oppenheimer | Perform |
| 2020-09-14 | 개시 | Guggenheim | Buy |
| 2020-08-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-05-31 | 재개 | H.C. Wainwright | Buy |
| 2018-11-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-10-12 | 다운그레이드 | Needham | Buy → Hold |
| 2018-10-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2017-11-08 | 재확인 | Needham | Buy |
| 2017-10-16 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2017-10-12 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-08 | 재확인 | Needham | Buy |
| 2017-02-23 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-22 | 재확인 | FBR & Co. | Outperform |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-01-09 | 개시 | H.C. Wainwright | Buy |
| 2017-01-05 | 개시 | Oppenheimer | Outperform |
| 2016-05-17 | 재확인 | FBR Capital | Outperform |
| 2016-05-17 | 재확인 | Needham | Buy |
| 2016-03-29 | 개시 | FBR Capital | Outperform |
| 2015-09-01 | 재확인 | Wedbush | Outperform |
| 2015-08-03 | 개시 | Brean Capital | Buy |
모두보기
Trevena Inc 주식(TRVN)의 최신 뉴스
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aviation Co. Says Workers' Class Action Too Broad - Law360
Block & Leviton Reminds Shareholders of Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN) - Defense World
Trevena (NASDAQ:TRVN) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Opioid Drugs Market Detailed In New Research Report 2025-2032 | - openPR.com
Trevena Delays Yearly Report Filing - TipRanks
Trevena (TRVN) Expected to Announce Quarterly Earnings on Monday - Defense World
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V - The Manila Times
Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com - Defense World
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times
Global Post Operative Pain Management Market Advancements Highlighted by Forecast: Key Growth Drivers, Tren... - WhaTech
Ten option delistings on March 24th - TipRanks
Trevena (NASDAQ:TRVN) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN) - The AM Reporter
Opioid Drugs Market to Witness Remarkable Growth with Johnson & Johnson, Endo International plc - openPR
Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com - Defense World
Trevena, Inc. to Host Earnings Call - ACCESS Newswire
Trevena (NASDAQ:TRVN) Now Covered by StockNews.com - Defense World
Opioid Drugs Market Growth, Demand Trends, Size & Competitive - openPR
Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com - Defense World
Promising Automotive Stocks To Keep An Eye On – February 04th - ETF Daily News
Trevena Announces Board and Executive ChangesOn January 31, 2025, Trevena, Inc. (NASDAQ:TRVN) filed a Form 8-K with the Securities and Exchange Commission, detailing significant departures and appointments within the company.In line with ongoin - Defense World
Trevena Implements Cost-Cutting Measures Amid Leadership Changes - TipRanks
Trevena (NASDAQ:TRVN) Shares Cross Below 200 Day Moving Average – Time to Sell? - Defense World
Trevena discontinues OLINVYK injection sales By Investing.com - Investing.com Canada
Trevena discontinues OLINVYK injection sales - Investing.com
Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com - Defense World
Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection - Reuters.com
Trevena Announces Reverse Stock Split to Regain Nasdaq Compliance - MSN
With a 1.8% CAGR, the Opioid Market is Expected to Reach USD 28.45 billion by 2034 | PMR - GlobeNewswire
Trevena's SWOT analysis: CNS drug developer's stock faces pivotal moment - Investing.com
Trevena's SWOT analysis: stock outlook amid pipeline focus and financial moves - Investing.com Canada
Trevena's SWOT analysis: stock outlook amid pipeline focus and financial moves By Investing.com - Investing.com South Africa
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Trevena Inc (TRVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):